| David Hafner, MD | |
|
2980 Squalicum Pkwy, Suite 304, Bellingham, WA 98225-1880 | |
| (360) 647-3377 | |
| (360) 752-3214 |
| Full Name | David Hafner |
|---|---|
| Gender | Male |
| Speciality | Anesthesiology |
| Experience | 30 Years |
| Location | 2980 Squalicum Pkwy, Bellingham, Washington |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1205800943 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207L00000X | Anesthesiology | MD60322718 (Washington) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| St Joseph Hospital | Bellingham, WA | Hospital |
| Cascade Valley Hospital | Arlington, WA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Bellingham Anesthesia Associates Ps | 6406755990 | 54 |
| Bellingham Anesthesia Associates Ps | 6406755990 | 54 |
News Archive
The Palmetto Health Board of Directors has unanimously approved the establishment of Palmetto Health Quality Collaborative, LLC, often referred to as an accountable care organization. The Quality Collaborative will be a physician-led, patient-centered, interdependent medical entity that focuses on best practices in clinical outcomes and evidence-based care. Palmetto Health will soon begin offering the more than 1,000 physicians on its medical staff an opportunity to join.
Researchers from Salk have found that two experimental drugs named CMS121 and J147 may improve memory functions and reduce the progression of memory decline and brain degeneration in mice models of Alzheimer's disease (AD). The researchers published their work in the latest issue of the journal eLife. The study was titled, "Elevating acetyl-CoA levels reduces aspects of brain aging."
A groundbreaking report, led by Professor Mark Lawler, Chair in Translational Cancer Genomics at Queen's University Belfast highlights a plan to end bowel cancer, the second most common cause of cancer death in Europe.
Neuroblastoma accounts for 15% of total childhood cancer deaths. The survival rate of high-risk neuroblastoma patients is 50%.
ImmunoGen, Inc., a biotechnology company that develops antibody-based anticancer products, today announced the presentation of positive initial clinical data with the Company's IMGN901 anticancer compound when used as part of a standard combination regimen to treat relapsed multiple myeloma.
› Verified 8 days ago
| Entity Name | Bellingham Anesthesia Associates Ps |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1609893460 PECOS PAC ID: 6406755990 Enrollment ID: O20040105000120 |
News Archive
The Palmetto Health Board of Directors has unanimously approved the establishment of Palmetto Health Quality Collaborative, LLC, often referred to as an accountable care organization. The Quality Collaborative will be a physician-led, patient-centered, interdependent medical entity that focuses on best practices in clinical outcomes and evidence-based care. Palmetto Health will soon begin offering the more than 1,000 physicians on its medical staff an opportunity to join.
Researchers from Salk have found that two experimental drugs named CMS121 and J147 may improve memory functions and reduce the progression of memory decline and brain degeneration in mice models of Alzheimer's disease (AD). The researchers published their work in the latest issue of the journal eLife. The study was titled, "Elevating acetyl-CoA levels reduces aspects of brain aging."
A groundbreaking report, led by Professor Mark Lawler, Chair in Translational Cancer Genomics at Queen's University Belfast highlights a plan to end bowel cancer, the second most common cause of cancer death in Europe.
Neuroblastoma accounts for 15% of total childhood cancer deaths. The survival rate of high-risk neuroblastoma patients is 50%.
ImmunoGen, Inc., a biotechnology company that develops antibody-based anticancer products, today announced the presentation of positive initial clinical data with the Company's IMGN901 anticancer compound when used as part of a standard combination regimen to treat relapsed multiple myeloma.
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| David Hafner, MD 2980 Squalicum Pkwy, Suite 304, Bellingham, WA 98225-1880 Ph: (360) 647-3377 | David Hafner, MD 2980 Squalicum Pkwy, Suite 304, Bellingham, WA 98225-1880 Ph: (360) 647-3377 |
News Archive
The Palmetto Health Board of Directors has unanimously approved the establishment of Palmetto Health Quality Collaborative, LLC, often referred to as an accountable care organization. The Quality Collaborative will be a physician-led, patient-centered, interdependent medical entity that focuses on best practices in clinical outcomes and evidence-based care. Palmetto Health will soon begin offering the more than 1,000 physicians on its medical staff an opportunity to join.
Researchers from Salk have found that two experimental drugs named CMS121 and J147 may improve memory functions and reduce the progression of memory decline and brain degeneration in mice models of Alzheimer's disease (AD). The researchers published their work in the latest issue of the journal eLife. The study was titled, "Elevating acetyl-CoA levels reduces aspects of brain aging."
A groundbreaking report, led by Professor Mark Lawler, Chair in Translational Cancer Genomics at Queen's University Belfast highlights a plan to end bowel cancer, the second most common cause of cancer death in Europe.
Neuroblastoma accounts for 15% of total childhood cancer deaths. The survival rate of high-risk neuroblastoma patients is 50%.
ImmunoGen, Inc., a biotechnology company that develops antibody-based anticancer products, today announced the presentation of positive initial clinical data with the Company's IMGN901 anticancer compound when used as part of a standard combination regimen to treat relapsed multiple myeloma.
› Verified 8 days ago
John Erik Schroeter, MD Anesthesiology Medicare: Medicare Enrolled Practice Location: 2980 Squalicum Pkwy, Suite 105, Bellingham, WA 98225 Phone: 360-647-3377 Fax: 360-752-3214 | |
Robert Kahn, MD Anesthesiology Medicare: Not Enrolled in Medicare Practice Location: 2901 Squalicum Pkwy, Bellingham, WA 98225 Phone: 360-734-5400 | |
Arjun Chenna Reddy, MD Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 909 Squalicum Way Ste 102, Bellingham, WA 98225 Phone: 606-473-3773 | |
Dr. Gregory Carl Sund, M.D. Anesthesiology Medicare: Medicare Enrolled Practice Location: 2980 Squalicum Pkwy, Suite 304, Bellingham, WA 98225 Phone: 360-647-3377 Fax: 360-752-3214 | |
Dr. John Edwin Morrison, M.D. Anesthesiology Medicare: Medicare Enrolled Practice Location: 909 Squalicum Way Ste 102, Bellingham, WA 98225 Phone: 360-647-3377 | |
Dr. Nishan Bingham, Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 909 Squalicum Way Ste 102, Bellingham, WA 98225 Phone: 360-647-3377 Fax: 360-752-3214 | |
Robert Todd Campbell, MD Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 2980 Squalicum Pkwy, Bellingham, WA 98225 Phone: 360-647-3377 Fax: 360-752-3214 |